Clinical Trial Protocol: QUILT -3.067 Phase 1b Primary Endpoint: • Incidence of treatment- emergent adverse events (AEs) and serious AEs (SAEs), graded using the National Cancer Institute (NCI) Co mmon Terminology Criteria for Adverse Events (CTCAE) Version 4.03. Secondary Endpoints: • ORR by RECIST Version 1.1 and irRC. • PFS by RECIST Version 1.1 and irRC. • OS. • DOR. • DCR (confirmed CR, PR, or stable disease [SD] lasting for at least 2 months). • QoL by PROs. Exploratory Endpoints: • Tumor molecular profiles and correlations with subject outcomes. • Therapy- induced changes in immune responses and correlations with subject outcomes. • Molecular changes in ctDNA and ctRNA and correlations with subject outcomes. Phase 2 Primary Endpoint: • ORR by RECIST Version 1.1 and irRC. Secondary Endpoints: • PFS by RECIST Version 1.1 and irRC. • OS.